Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
Q3 FY26 Earnings Results
- Revenue from Operations: Consolidated ₹196 cr, +18% YoY vs ₹166 cr, total income ₹200.51 cr; standalone ₹183 cr (+20% YoY), ₹185.91 cr total income; pathology drove 93% growth with franchisee +12% YoY to ₹112 cr, partnerships +39% YoY to ₹60 cr.
- EBITDA: Reported EBITDA +38% YoY, margins expanded on operating leverage, higher volumes; radiology dipped but diagnostics offset.
- PAT: Consolidated ₹28.05 cr (+47% YoY vs ₹19.1 cr), standalone ₹26.15 cr (+37% YoY); EPS basic ₹1.82 consolidated (+58% YoY); 9M consolidated PAT ₹114.15 cr (+65% YoY), revenue ₹618 cr (+21% YoY).
- Other key metrics: Tests 49.6 mn (+22% YoY), patients 4.5 mn (+14% YoY), active franchisees 10,300 (+12% YoY), complaints/1mn tests 3.2 (−43% YoY), NABL labs 97%; 9M standalone PAT ₹105.23 cr (+42% YoY).
Management Commentary & Strategic Decisions
- Strong diagnostics momentum with volume/margin tailwinds, franchise expansion; radiology softness noted but overall execution robust amid demand.
- Strategic moves: Lab network/franchisee ramp-up, quality focus (97% NABL), Madhuri Dixit brand ambassador; code of conduct amendments for insiders; earnings call Jan 28.
Q2 FY26 Earnings Results
- Revenue from Operations: Consolidated ₹216.5 cr (+22% YoY vs ₹177 cr), +12% QoQ; standalone ₹202 cr (+24% YoY); diagnostics >93%, imaging ₹14.2 cr.
- EBITDA: Margin 33% (+expansion YoY), expenses +10% YoY lagging revenue.
- PAT: Consolidated ₹47.9 cr (+81% YoY vs ₹26.4 cr), standalone ₹43 cr (+48% YoY); H1 PAT ₹86.1 cr (+71% YoY).
- Other key metrics: H1 revenue +22% YoY; bonus issue 2:1, interim dividend ₹7/share; costs: materials ₹59.8 cr, employees ₹33.2 cr.
Management Commentary Q2
- Stellar growth via testing volumes, leverage; diagnostics/imaging synergy building.
- Strategic moves: Bonus 2:1, dividend ₹7/share (record Oct 24); H1 sets positive FY26 trajectory.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.